DNA-based colon cancer test backed by U.S. advisers

the ONA take:

An outside panel of experts advising the FDA gave their unanimous recommendation for the use of a colon cancer screening method that examines DNA samples taken from patient stool samples. The test detected 92.3 percent of colorectal cancers in average-risk patients in a large clinical trial and may be preferable in instances to traditional colonoscopy, which, although accurate, is a test avoided by many.

DNA-based colon cancer test backed by U.S. advisers
DNA-based colon cancer test backed by U.S. advisers
(Reuters) - A colon cancer screening method that uses stool samples won the unanimous backing of a U.S. advisory panel on Thursday, paving the way for potential regulatory approval of the DNA test.
READ FULL ARTICLE From Reuters
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs